<DOC>
	<DOCNO>NCT00312611</DOCNO>
	<brief_summary>The purpose study evaluate efficacy safety Transneuronix IGS System population patient BMI 35 55 .</brief_summary>
	<brief_title>Screened Health Assessment &amp; Pacer Evaluation</brief_title>
	<detailed_description>The purpose study evaluate efficacy safety Transneuronix IGS System population patient BMI 35 55 . Initially , maximum 150 patient follow 12 month randomize , placebo-controlled , double-blind , multi-center study evaluate efficacy safety IGS . All patient implant IGS System randomize control group ( IGS OFF ) treatment group ( IGS ON ) . Both group follow 500kcal/day-deficit diet ( Appendix A ) participate monthly support group meeting ( Appendix E ) . The study last 24 month randomization . The sponsor plan submit PreMarket Approval ( PMA ) application patient complete 12 month post-randomization follow-up . After 12 month randomization , patient continue follow monthly another year , patient receive gastric electrical stimulation long-term efficacy safety maintenance weight loss evaluate . After 24 month randomization , remain patient option enter extension study additional four year , long-term efficacy safety maintenance weight loss continue evaluate .</detailed_description>
	<criteria>1 ) Ability give inform consent 2 ) 18 65 year age time screen 3 ) BMI 35 55 time screen 4 ) Women childbearing potential ( i.e. , postmenopausal surgically sterilize ) must agree use adequate birth control method . Acceptable birth control method limit oral contraceptive , implant , diaphragm , IUDs , condom without spermicide , voluntary abstinence . The method birth control must document verified followup . 5 ) Patients report history five year obesity ( BMI &gt; 30 ) 6 ) Patients require pharmacological therapy psychological disorder , either study entry implant , must obtain letter license psychologist/psychiatrist justify use medication psychological reason ( Appendix D ) . 7 ) Patients must agree follow dietary component protocol outline Appendix A attend monthly support group meeting ( Appendix E ) . 8 ) Patients must geographically stable reside within 2hour commute clinical site ( determined investigator study coordinator ) able willing travel clinical site followup visit monthly support group meeting . 1 ) Patients exclude screen algorithm18 , 19 , 22 ( Appendix C ) 2 ) Patients score 29 high Binge Eating Scale Questionnaire ( Appendix F ) 3 ) Patients undergo psychological evaluation license psychologist psychiatrist ( Appendix D ) . Patients substance abuser identify borderline personality , bipolar disorder , disorder would make inappropriate candidate , opinion psychologist/psychiatrist . 4 ) Pregnant lactate female 5 ) Prior surgery GI tract therapy obesity 6 ) Prior surgery stomach reason 7 ) Other electrical stimulation device 8 ) Patients known history treatment ulcer 9 ) Patients clinically significant hiatal hernia 10 ) Patients motility disorder GI tract gross esophageal motility disorder , gastroparesis intractable constipation 11 ) Patients take weight loss medication drug affect body weight ( e.g . mirtazapine , laxatives , systemic glucocorticoid , neuroleptic agent , progestational steroid ) within three month prior screen 12 ) Patients require continuous therapy know ulcerogenic medication ( e.g. , aspirin , nonsteroidal antiinflammatory agent , COX2 inhibitor ) 13 ) Patients history cardiac arrhythmia severe cardiac disease ( NYHA class III IV ) 14 ) Type I diabetes poorly control Type II diabetes evidence HbA1c level great 10 % . Those patient HbA1c 8 % 10 % ongoing symptom hyperglycemia , include unexplained weight loss significant polyuria , polydipsia , fast glucose level 180 mg/dl* within 5 day prior implantation , exclude . * If fasting glucose level 180 mg/dl screening , patient exclude study treat hyperglycemia . Laboratory test , include fast glucose level , repeat patient within 5 day prior implantation . 15 ) Any diabetic patient nonsteady treatment thiazolidinediones ( Actos Avandia ) within past three month prior screen 16 ) Patients history Barrett 's esophagus 17 ) Patients severe weightrelated comorbid disease require immediate weight loss ( e.g. , lifethreatening sleep apnea ) 18 ) Patients serious health condition relate weight 19 ) Use another investigational agent within 30 day prior screen 20 ) Patients investigator study coordinator considers unable unwilling fulfill study requirement</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Gastric pacing device</keyword>
	<keyword>Obesity</keyword>
</DOC>